Altimmune (ALT) Gains from Investment Securities (2012 - 2026)
Altimmune (ALT) reported Gains from Investment Securities of $12.1 million for Q1 2026, up 1683.46% year-over-year from $678000.0 in Q1 2025, and up 48267.42% on a QoQ basis from $25000.0 in Q4 2025.
Altimmune (ALT) has 14 years of Gains from Investment Securities data on file, last reported at $12.1 million in Q1 2026.
- Quarterly Gains from Investment Securities rose 1683.46% year-over-year to $12.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.1 million (up 818.14% YoY) and the FY2025 annual result came in at $11.3 million, up 70.27% from the prior year.
- Gains from Investment Securities advanced to $12.1 million in Q1 2026 per ALT's latest filing, from $25000.0 in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $12.1 million in Q1 2026 and bottomed at -$1.8 million in Q1 2022.
- The 5-year median for Gains from Investment Securities is $678000.0 (2025), against an average of $3.1 million.
- Peak annual rise in Gains from Investment Securities reached 22302.09% in 2022, while the deepest fall reached 304.55% in 2022.
- Tracing ALT's Gains from Investment Securities over 5 years: stood at -$305000.0 in 2022, then soared by 112.13% to $37000.0 in 2023, then plunged by 94.59% to $2000.0 in 2024, then soared by 1150.0% to $25000.0 in 2025, then soared by 48267.42% to $12.1 million in 2026.
- Per Business Quant, the three latest ALT Gains from Investment Securities figures stand at $12.1 million (Q1 2026), $25000.0 (Q4 2025), and $8.7 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Altimmune | 379.61 Mn | 379.61 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 12.09 Mn |
| Mar 31, 2026 | 12.09 Mn |
| Dec 31, 2025 | 25,000.00 |
| Dec 31, 2025 | 25,000.00 |
| Sep 30, 2025 | 8.66 Mn |
| Sep 30, 2025 | 8.66 Mn |
| Jun 30, 2025 | 8.10 Mn |
| Jun 30, 2025 | 8.10 Mn |
| Mar 31, 2025 | 678,000.00 |
| Mar 31, 2025 | 678,000.00 |
| Dec 31, 2024 | 2,000.00 |
| Dec 31, 2024 | 2,000.00 |
| Sep 30, 2024 | 348,533.00 |
| Sep 30, 2024 | 348,533.00 |
| Jun 30, 2024 | 6.28 Mn |
| Jun 30, 2024 | 6.28 Mn |
| Mar 31, 2024 | 600,000.00 |
| Mar 31, 2024 | 600,000.00 |
| Dec 31, 2023 | 37,000.00 |
| Dec 31, 2023 | 37,000.00 |
| Sep 30, 2023 | 5.08 Mn |
| Sep 30, 2023 | 5.08 Mn |
| Jun 30, 2023 | 4.83 Mn |
| Jun 30, 2023 | 4.83 Mn |
| Mar 31, 2023 | 485,000.00 |
| Mar 31, 2023 | 485,000.00 |
| Dec 31, 2022 | -305,000.00 |
| Dec 31, 2022 | -305,000.00 |
| Sep 30, 2022 | 3.53 Mn |
| Sep 30, 2022 | 3.53 Mn |
| Jun 30, 2022 | 3.36 Mn |
| Jun 30, 2022 | 3.36 Mn |
| Mar 31, 2022 | -1.80 Mn |
| Mar 31, 2022 | -1.80 Mn |
| Dec 31, 2021 | -860,000.00 |
| Dec 31, 2021 | -860,000.00 |
| Sep 30, 2021 | 2.61 Mn |
| Sep 30, 2021 | 2.61 Mn |
| Jun 30, 2021 | 15,000.00 |
| Jun 30, 2021 | 15,000.00 |
| Mar 31, 2021 | 880,000.00 |
| Mar 31, 2021 | 880,000.00 |
| Dec 31, 2020 | 5.40 Mn |
| Dec 31, 2020 | 5.40 Mn |
| Sep 30, 2020 | 15,000.00 |
| Sep 30, 2020 | 15,000.00 |
| Jun 30, 2020 | 109,525.00 |
| Jun 30, 2020 | 109,525.00 |
| Mar 31, 2020 | 1.42 Mn |
| Mar 31, 2020 | 1.42 Mn |
| Sep 30, 2019 | 976,861.00 |
| Sep 30, 2019 | 976,861.00 |
| Jun 30, 2019 | 873,066.00 |
| Jun 30, 2019 | 873,066.00 |
| Mar 31, 2019 | 900,869.00 |
| Mar 31, 2019 | 900,869.00 |
| Dec 31, 2018 | -2.87 Mn |
| Dec 31, 2018 | -2.87 Mn |
| Sep 30, 2018 | 806,224.00 |
| Sep 30, 2018 | 806,224.00 |
| Jun 30, 2018 | -1.64 Mn |
| Jun 30, 2018 | -1.64 Mn |
| Mar 31, 2018 | 134,500.00 |
| Mar 31, 2018 | 134,500.00 |
| Dec 31, 2017 | -5,437.00 |
| Dec 31, 2017 | -5,437.00 |
| Sep 30, 2017 | -508,316.00 |
| Sep 30, 2017 | -508,316.00 |
| Jun 30, 2017 | 1.47 Mn |
| Jun 30, 2017 | 1.47 Mn |
| Mar 31, 2017 | -1,416.00 |
| Mar 31, 2017 | -1,416.00 |
| Dec 31, 2016 | 52,807.00 |
| Dec 31, 2016 | 52,807.00 |
| Sep 30, 2016 | -54,071.00 |
| Sep 30, 2016 | -54,071.00 |
| Jun 30, 2016 | 6,172.00 |
| Jun 30, 2016 | 6,172.00 |
| Mar 31, 2016 | -5,485.00 |
| Mar 31, 2016 | -5,485.00 |
| Sep 30, 2015 | 4.40 Mn |
| Sep 30, 2015 | 4.40 Mn |
| Jun 30, 2015 | 3.70 Mn |
| Jun 30, 2015 | 3.70 Mn |
| Mar 31, 2015 | 7,600.00 |
| Mar 31, 2015 | 7,600.00 |
| Dec 31, 2014 | 1.00 |
| Dec 31, 2014 | 1.00 |
| Mar 31, 2014 | 5,393.00 |
| Mar 31, 2014 | 5,393.00 |
| Sep 30, 2012 | 1.60 Mn |
| Sep 30, 2012 | 1.60 Mn |
| Jun 30, 2012 | 1.60 Mn |
| Jun 30, 2012 | 1.60 Mn |
| Mar 31, 2012 | 66,626.00 |
| Mar 31, 2012 | 66,626.00 |